Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole

Table 1 Demographic and other baseline characteristics in the randomized set (n = 607)¹

Characteristic	LPZ 15 mg (n = 201)	VPZ 10 mg (n = 202)	VPZ 20 mg (n = 204)
Age, yr	57.8 ± 12.9	55.5 ± 13.8	56.8 ± 13.6
Gender, male	140 (69.7)	160 (79.2)	160 (78.4)
Height, cm	163.5 ± 10.2	165.5 ± 9.3	165.6 ± 9.3
Weight, kg	67.0 ± 13.4	68.2 ± 12.3	69.0 ± 13.1
Erosive esophagitis grade, investigator-assessed
LA Grade A/B	160 (79.6)	162 (80.2)	161 (78.9)
LA Grade C/D	41 (20.4)	40 (19.8)	43 (21.1)
Esophageal hiatal hernia
≥ 2 cm	31 (15.4)	45 (22.3)	46 (22.5)
< 2 cm	105 (52.2)	100 (49.5)	113 (55.4)
None	65 (32.3)	57 (28.2)	44 (21.6)
H. pylori infection status
Positive	29 (14.4)	37 (18.3)	23 (11.3)
Negative	172 (85.6)	165 (81.7)	181 (88.7)
CYP2C19 genotype
Extensive metabolizers	162 (80.6)	169 (84.1)	169 (83.3)
Poor metabolizers	39 (19.4)	32 (15.9)	34 (16.7)

¹Values expressed as mean ± SD, or n (%). LA: Los Angeles; LPZ: Lansoprazole; SD: Standard deviation; VPZ: Vonoprazan.